Premium
Neoadjuvant gemcitabine and cisplatin: Another step on the path toward improving the outcomes of patients with high‐risk, invasive bladder cancer
Author(s) -
Nielsen Matthew E.
Publication year - 2008
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23849
Subject(s) - medicine , gemcitabine , cisplatin , vinblastine , oncology , bladder cancer , neoadjuvant therapy , chemotherapy , methotrexate , cancer , urology , breast cancer
Until such time as there are data from prospective randomized trials directly comparing neoadjuvant cisplatin and gemcitabine (GC) to neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin, the data presented in the study by Dash et al in this issue of Cancer provide strong support for the consideration of neoadjuvant GC as an effective and well‐tolerated component in the armamentarium against high‐risk bladder cancer.